Tag Archives: NSCLC

NICE Updates Recommendations for Second Line Treatment NSCLC

In light of NICE’S latest policy change, Steven Bradshaw comments on how this decision will effect second line treatment of non-small cell lung cancer.

Dr Steven Bradshaw, Medical Expert

As a regularly-published medical expert with a significant degree of experience in HTA submissions and market access of pharmaceuticals, Dr Steven Bradshaw act as a consultant to some of the top pharmaceuticals companies, healthcare research organizations and government think tanks in the world. Continue reading